Kilitch Drugs (India) Ltd
company logo

Kilitch Drugs (India) Ltd

KILITCH Share Price

BSE:524500

NSE:KILITCH

128.06

-3.83 (-2.90%)

As on April 10, 2026 at 03:50 PM
Loading chart...

Performance

Loading performance...

131.89

131.27

56383

0.72

10

Fundamentals

463.77Cr

17.81

1.75

0.21

7.45

0%

75.99

About

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe. Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions. The Company went public in Feb.'94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules, liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.'95 to expand the capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions - O T C and ethical. A Pharmaceutical formulation plant at Sana'a Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with Al-Fath Trading Corporation. It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America. The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5-cr tanning unit, which was implemented in the year 1995-96. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middle-east, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clue-plus, Bon-Bon Gripe Water and Kilitch Balm. The Company launched a new product 'BENIN' in the market in 2011. During the year 2011-12, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.

Mukund P Mehta

1992

KILITCH

NameDesignation
Mukund P MehtaChairman & Managing Director
Bhavin M MehtaWTD & Executive Director
Mira MehtaManaging Director
VASUDEV KRISHNAMURTIIndependent Non Exe. Director
Venkita Subramanian RajanIndependent Non Exe. Director
DIPEN JAYANTILAL JAINIndependent Non Exe. Director
Pushpa NyoupaneCompany Sec. & Compli. Officer

Kilitch Drugs (India) Ltd FAQs

How do I Buy Kilitch Drugs (India) Ltd Shares?

close

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Kilitch Drugs (India) Ltd shares in BlinkX.

What is the Share Price of Kilitch Drugs (India) Ltd?

close

The share price of any stock is volatile and changes during the day due to a variety of variables. Kilitch Drugs (India) Ltd's share price is ₹128.06 as of 2026-04-10.

What is the PE ratio of Kilitch Drugs (India) Ltd?

close

Kilitch Drugs (India) Ltd's P/E ratio is 17.81 times as of 2026-04-10.

What is the PB ratio of Kilitch Drugs (India) Ltd?

close

Kilitch Drugs (India) Ltd's most recent financial reports indicate a price-to-book ratio of 1.75, showing the company's stock market valuation in relation to the value of its real assets.

What is the Market Cap of Kilitch Drugs (India) Ltd?

close

Market capitalization, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Kilitch Drugs (India) Ltd's market capitalization is ₹463.77 Cr as on 2026-04-10.

What is the ROE of Kilitch Drugs (India) Ltd?

close

The current financial records of Kilitch Drugs (India) Ltd show a 11.02% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

What is the Total Asset of Kilitch Drugs (India) Ltd?

close

According to Kilitch Drugs (India) Ltd's most recent financial filings, the company has a total asset value of ₹115.74, which includes current and non-current assets such as inventory, cash, properties, and equipment.

What is the 52-week high and Low of Kilitch Drugs (India) Ltd?

close

The 52-week high/low price of a Kilitch Drugs (India) Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Kilitch Drugs (India) Ltd's 52-week high and low as of 2026-04-10 are ₹250 and ₹117.25, respectively.